

Medexus Pharmaceuticals Inc

16:04 22 May 2020

Medexus Pharmaceuticals sees steady growth across key product lines as it updates on IXINITY acquisition

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) told investors that the acquisition of hematology asset IXINITY had been highly accretive to the firm in its fiscal fourth quarter and that it was well positioned to emerge stronger when the economy reopens after the coronavirus (COVID-19) crisis.

The firm closed its acquisition of Aptevo BioTherapeutics LLC, which owns the worldwide rights to IXINITY from Nasdaq-listed Aptevo Therapeutics Inc, on February 28 this year and integration of the product is progressing as expected.

READ: Medexus Pharmaceuticals secures US\$20M credit facility, pays off term loan

Medexus sees significant further growth potential for sales as it leverages its expanded sales force in the US. To that end, Michael Adelman, from Aptevo, has been appointed general manager of Medexus' US operations.

Medexus said its fiscal fourth quarter ended March 31, 2020, included two months of pre-acquisition sales and one month post-acquisition.

Preliminary unaudited sales estimates for IXINITY during the fiscal fourth quarter was US\$8.3 million, representing an 18.5% year-over-year increase, noted Medexus.

"Approximately 85% of those IXINITY sales accrued to the benefit of Medexus post-acquisition and as such, the addition of IXINITY was highly accretive to Medexus for the quarter," it added.

The revenues from IXINITY for March 2020 are in line with Medexus' expectations, it added.

On May 7, Medexus announced the completion of a financing deal with MidCap Financial Trust on a secured 38 month revolving credit facility.

The ABL Facility features a US\$20 million revolving commitment and uncommitted US\$10 million accordion. The financing package allowed Medexus to finance the acquisition without issuing further shares, it said.

On the pandemic, Medexus said it continues to address operational challenges posed by the virus but it has largely been successful in conducting business as usual.


So far, no employees have reported testing positive for the COVID-19 virus, said the company.

"Medexus' business remains strong and is well positioned to emerge even stronger as the economy reopens," Medexus chairman Peter van der Velden said in a statement.

Price: 2.5

Market Cap: \$35.15 m

1 Year Share Price Graph



Share Information

Code: MDP

Listing: TSX-V

52 week High Low
5 1.42

Sector: Pharma & Biotech

Website: www.medexusinc.com

Company Synopsis:

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, pediatrics, and specialty oncology.

action@proactiveinvestors.com

"We continue to generate steady growth across our key product lines and, despite the disruption from the COVID-19 pandemic, our sales teams have continued to be remarkably productive by finding new ways to connect creatively and productively with clinicians and patients.

"As much of our portfolio is used to treat chronic conditions, we continue to see strong demand for our products, including our new hematology product, IXINITY. While continuing to be very disciplined about how we manage our cash, we are excited about the expanding list of compelling business development opportunities our team is evaluating."

Shares in Toronto added over 12% at C\$2.81 each.

---Updates for share price---

Contact the author at giles@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount of up to Twenty Five Thousand dollars (\$25,000).